A gene essentiality signature for studying the mechanism of action of drugs
Wang, W.; Bao, J.; Zheng, S.; Huang, S.; Aldahdooh, J.; Wang, Y.; Eriksson, J. T.; Tanoli, Z.; Tang, J.
Show abstract
Cancer drugs often kill cells independent of their putative targets, suggesting the limitation of existing knowledge on the mechanisms of action. In this study, we explored whether the integration of loss-of-function genetic and drug sensitivity screening data can define a gene essentiality signature to better understand the drug target interactions. We showed that our gene essentiality signature can predict drug targets more accurately than chemical fingerprints and drug-perturbated gene expression signatures. We further showed how gene essentiality signature can help identify mechanisms of action of drugs de novo, including the EGFR inhibitor lapatinib, and drugs associated with DNA mismatch repair. Finally, we established gene essentiality signatures for noncancer drugs and used them to predict their anticancer targets. We have successfully validated the target predictions for multiple noncancer drugs, using cell-based drug target deconvolution by the proteome integral solubility alteration assay. Our study provides a novel signature of drugs that may facilitate the rational design of drug repurposing.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Defining subpopulations of differential drug response to reveal novel target populations 98%
- Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors 97%
- Stratification and prediction of drug synergy based on target functional similarity 94%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 92%
- Inhibition of both mutant and wild-type RAS-GTP in KRAS G12C colorectal cancer through cotreatment with G12C and EGFR inhibitors 91%
- Generalizing AI-driven Assessment of Immunohistochemistry across Immunostains and Cancer Types: A Universal Immunohistochemistry Analyzer 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.